| Title |
Adeno-associated virus-mediated expression of recombinant CBD–HepII polypeptide of human fibronectin inhibits metastasis of breast cancer
|
|---|---|
| Published in |
Breast Cancer Research and Treatment, November 2013
|
| DOI | 10.1007/s10549-013-2783-8 |
| Pubmed ID | |
| Authors |
Zhen-Hui He, Zhang Lei, Yan Zhen, Wei Gong, Bo Huang, Ye Yuan, Gui-Mei Zhang, Xiao-Juan Wang, Zuo-Hua Feng |
| Abstract |
CH50, a recombinant CBD-HepII polypeptide of human fibronectin, was shown to suppress tumor metastasis in murine hepatocarcinoma and melanoma models. However, the effect of CH50 on human cancer cells is still not clear. Here we evaluated the efficiency of CH50 delivered by recombinant adeno-associated virus (rAAV) vector for breast cancer treatment. Infection of the two human breast cancer cell line MDA-MB-231 and MDA-MB-468 with a rAAV2 vector encoding CH50 resulted in secretion of soluble CH50. In vitro rAAV-CH50 transduction inhibited adhesion to ECM molecules, and transwell migration and invasion of breast cancer cells induced by fibronectin. In both breast cancer cells, rAAV-CH50 targeted αVβ3 signaling, namely inhibited the expression of αVβ3, the activation of FAK, the upregulation of cdc2, and the production and activation of MMP-9 by ECM molecules stimulation. rAAV-mediated tail vein transfusion and stable expression of CH50 in the liver resulted in the long-term presence of CH50 in sera of nude mice. Sustained CH50 expression mediated by rAAV vector suppressed the growth and spontaneous metastasis of orthotopic breast cancer xenograft, experimental metastasis of circulating breast cancer cells, and improved the long-term survival of breast tumor-bearing mice. These findings suggest for the first time that rAAV-CH50 gene therapy may present a novel and promising strategy for treatment against metastatic breast cancer. |
X Demographics
The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 1 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 1 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 19 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 1 | 5% |
| Unknown | 18 | 95% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Ph. D. Student | 5 | 26% |
| Student > Bachelor | 4 | 21% |
| Student > Master | 3 | 16% |
| Professor | 1 | 5% |
| Other | 1 | 5% |
| Other | 2 | 11% |
| Unknown | 3 | 16% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 3 | 16% |
| Agricultural and Biological Sciences | 3 | 16% |
| Engineering | 2 | 11% |
| Biochemistry, Genetics and Molecular Biology | 1 | 5% |
| Pharmacology, Toxicology and Pharmaceutical Science | 1 | 5% |
| Other | 4 | 21% |
| Unknown | 5 | 26% |
Attention Score in Context
This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 05 December 2013.
All research outputs
#20,211,690
of 22,733,113 outputs
Outputs from Breast Cancer Research and Treatment
#4,103
of 4,649 outputs
Outputs of similar age
#267,071
of 306,616 outputs
Outputs of similar age from Breast Cancer Research and Treatment
#63
of 71 outputs
Altmetric has tracked 22,733,113 research outputs across all sources so far. This one is in the 1st percentile – i.e., 1% of other outputs scored the same or lower than it.
So far Altmetric has tracked 4,649 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 7.2. This one is in the 1st percentile – i.e., 1% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 306,616 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 1st percentile – i.e., 1% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 71 others from the same source and published within six weeks on either side of this one. This one is in the 1st percentile – i.e., 1% of its contemporaries scored the same or lower than it.